Holen Sie sich die Stockscreener-App
10.64
0.65%
-0.07
Schlusskurs vom Vortag:
$10.71
Offen:
$10.77
24-Stunden-Volumen:
973.33K
Relative Volume:
0.92
Marktkapitalisierung:
$661.32M
Einnahmen:
$840.00K
Nettoeinkommen (Verlust:
$-75.20M
KGV:
-6.683
EPS:
-1.5921
Netto-Cashflow:
$-65.69M
1W Leistung:
-4.83%
1M Leistung:
-28.06%
6M Leistung:
+79.12%
1J Leistung:
+104.62%
1-Tages-Spanne:
$10.38
$10.78
1-Wochen-Bereich:
$10.38
$11.41
52-Wochen-Spanne:
$4.19
$17.58
Silence Therapeutics Plc Adr Stock (SLN) Company Profile
Firmenname
Silence Therapeutics Plc Adr
Sektor
Branche
Telefon
44-0-20-3457 6900
Adresse
12 HAMMERSMITH GROVE, LONDON
Compare SLN vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLN
Silence Therapeutics Plc Adr
|
10.64 | 694.88M | 840.00K | -75.20M | -65.69M | -1.5921 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Silence Therapeutics Plc Adr Stock (SLN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-11 | Eingeleitet | Goldman | Sell |
| 2024-12-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2024-09-03 | Eingeleitet | Jefferies | Buy |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Outperform |
Silence Therapeutics Plc Adr Aktie (SLN) Neueste Nachrichten
Silence Therapeutics at H.C. Wainwright conference: divesiran drives focus By Investing.com - Investing.com UK
Silence Therapeutics at Cantor healthcare conference: divesiran advances By Investing.com - Investing.com South Africa
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga
Zai Lab LimitedADR Peer Comparison – Compare with Others - Value Research
Mesoblast LimitedADR Peer Comparison – Compare with Others - Value Research
Pharming Group N.V. ADS each representing 10 (PHAR) Peer Comparison – Compare with Others - Value Research
Purple Biotech (PPBT) Peer Comparison – Compare with Others - Value Research
DBV Technologies S.A.ADR Peer Comparison – Compare with Others - Value Research
Neuraxis Inc. (NRXS) Peer Comparison – Compare with Others - Value Research
ProMIS Neurosciences Inc. (PMN) Peer Comparison – Compare with Others - Value Research
Silence Therapeutics (NASDAQ:SLN) Sees Strong Trading VolumeShould You Buy? - MarketBeat
What is HC Wainwright's Estimate for SLN Q3 Earnings? - MarketBeat
Investors Buy High Volume of Silence Therapeutics Call Options (NASDAQ:SLN) - MarketBeat
Silence Therapeutics closes $201.3M public offering By Investing.com - Investing.com India
Silence Therapeutics closes $201.3M public offering - Investing.com
Silence Therapeutics Director Richard Ian Griffiths Reports Multiple ADS Sales on August 10, 2026 - Kalkine Media
Wall Street Analysts Predict a 140.06% Upside in Silence Therapeutics (SLN): Here's What You Should Know - Yahoo Finance
Silence Therapeutics Announces Pricing of $13.50 Per ADS in Public Offering - Kalkine Media
Form 8K Silence Therapeutics plc For: 12 August By Investing.com - Investing.com India
Silence Therapeutics (NASDAQ:SLN) Shares Down 6.9%What's Next? - MarketBeat
Silence Therapeutics prices $175M public offering at $13.50 per ADS - Investing.com
Why Avalon Holdings Shares Are Trading Higher By More Than 10%; Here Are 20 Stocks Moving Premarket - Sahm
Silence Therapeutics (NASDAQ:SLN) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Silence Therapeutics’ Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial - sharewise.com
Silence Therapeutics Jumps Over 25% After Divesiran Phase 2 Trial Supports 12-Week Dosing - TechStock²
Silence Therapeutics launches $150 million public offering - Investing.com
Silence Therapeutics launches $150 million public offering By Investing.com - Investing.com India
Silence Therapeutics (NASDAQ:SLN) Shares Gap UpStill a Buy? - MarketBeat
Silence Therapeutics Reports Q2 2026 Financial Results in SEC Filing - Kalkine Media
Silence Therapeutics Announces Positive Phase 2 SANRECO Trial Outcomes for Divesiran in Polycythemia Vera - Kalkine Media
Silence Therapeutics SLN Stock Heats Up Ahead Phase 2 Data - StocksToTrade
Silence Therapeutics (SLN) Rallies Ahead Of Key Phase 2 Data - timothysykes.com
Silence Therapeutics reports positive phase 2 trial results - Investing.com
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile - Finviz
Why is Silence Therapeutics stock surging today? By Investing.com - Investing.com South Africa
Silence Therapeutics (NASDAQ:SLN) Reaches New 1-Year HighStill a Buy? - MarketBeat
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
SLN Q4 2024 Earnings: EPS of $0.2131 Reported; Shares Decline 9.72Pretax Income Report - careplusvn.com
ADAR1 Capital Management LLC Buys 148,514 Shares of Silence Therapeutics PLC Sponsored ADR $SLN - MarketBeat
Silence Therapeutics (NASDAQ:SLN) Sees Large Volume IncreaseStill a Buy? - MarketBeat
Silence Therapeutics (NASDAQ:SLN) Reaches New 12-Month HighTime to Buy? - MarketBeat
Silence Therapeutics (NASDAQ:SLN) Stock Price Up 6.9%Here's Why - MarketBeat
SLN stock skyrockets 107% in six months: Here's what you need to know - MSN
Silence Therapeutics (SLN) moves 7.2% higher: Will this strength last? - MSN
ETFs Investing in Silence Therapeutics PLC Sponsored ADR Stocks - TradingView
SLN Stock Skyrockets 107% in Six Months: Here's What You Need to Know - Yahoo Finance UK
Silence Therapeutics (SLN) Moves 7.2% Higher: Will This Strength Last? - Yahoo Finance Singapore
Silence Therapeutics (NASDAQ:SLN) Shares Up 10%Here's What Happened - MarketBeat
Form 13D/A Silence Therapeutics Plc For: 8 July By Investing.com - Investing.com South Africa
Silence Therapeutics (SLN) surges 26.0%: Is this an indication of further gains? - MSN
Silence Therapeutics PLC Sponsored ADR Actuals & Estimates (NASDAQ:SLN) - TradingView
Finanzdaten der Silence Therapeutics Plc Adr-Aktie (SLN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):